Naveen R, Nikiphorou E, Joshi M, Sen P, Lindblom J, Agarwal V, Lilleker JB, Tan AL, Salim B, Ziade N, Velikova T, Gracia-Ramos AE, Kuwana M, Day J, Makol A, Distler O, Chinoy H, Wibowo SAK, Serrano JR, García-De La Torre I, Barman B, Singh YP, Ranjan R, Jain A, Pandya SC, Pilania RK, Sharma A, Manesh Manoj M, Gupta V, Kavadichanda CG, Patro PS, Ajmani S, Phatak S, Goswami RP, Chowdhury AC, Mathew AJ, Shenoy P, Asranna A, Bommakanti KT, Shukla A, Pandey AKR, Chandwar K, Kardeş S, Cansu DÜ, Kim M, Makol A, Chatterjee T, Pauling JD, Wincup C, Cavagna L, Del Papa N, Sambataro G, Fabiola A, Govoni M, Parisi S, Bocci EB, Sebastiani GD, Fusaro E, Sebastiani M, Quartuccio L, Franceschini F, Sainaghi PP, Orsolini G, De Angelis R, Danielli MG, Venerito V, Milchert M, Traboco LS, Wibowo SAK, Tehozol EAZ, Serrano JR, García-De La Torre I, Loarce-Martos J, Prieto-González S, Gil-Vila A, Gonzalez RA, Kuwana M, Yoshida A, Nakashima R, Sato S, Kimura N, Kaneko Y, Knitza J, Tomaras S, Gromova MA, Aharonov O, Gheita TA, Hmamouchi I, Hoff LS, Giannini M, Maurier F, Campagne J, Meyer A, Nagy-Vincze M, Langguth D, Limaye V, Needham M, Srivastav N, Hudson M, Landon-Cardinal O, Shaharir SS, Zuleta WGR, Silva JAP, Fonseca JE, Zimba O, Aggarwal R, Gupta L, Agarwal V, Parodis I (2023)
Publication Type: Journal article
Publication year: 2023
Book Volume: 62
Pages Range: 2453-2463
Journal Issue: 7
DOI: 10.1093/rheumatology/keac661
OBJECTIVE: To determine COVID-19 vaccine-related adverse events (AEs) in the seven-day post-vaccination period in patients with SLE vs autoimmune rheumatic diseases (AIRDs), non-rheumatic autoimmune diseases (nrAIDs), and healthy controls (HC). METHODS: Data were captured through the COVID-19 Vaccination in Autoimmune Diseases (COVAD) questionnaire (March-December 2021). Multivariable regression models accounted for age, gender, ethnicity, vaccine type and background treatment. RESULTS: Among 9462 complete respondents, 583 (6.2%) were SLE patients (mean age: 40.1 years; 94.5% females; 40.5% Asian; 42.9% Pfizer-recipients). Minor AEs were reported by 83.0% of SLE patients, major by 2.6%, hospitalization by 0.2%. AE and hospitalization frequencies were similar between patients with active and inactive SLE. Rashes were more frequent in SLE patients vs HC (OR; 95% CI: 1.2; 1.0, 1.5), chills less frequent in SLE vs AIRDs (0.6; 0.4, 0.8) and nrAIDs (0.5; 0.3, 0.8), and fatigue less frequent in SLE vs nrAIDs (0.6; 0.4, 0.9). Pfizer-recipients reported higher overall AE (2.2; 1.1, 4.2) and injection site pain (2.9; 1.6, 5.0) frequencies than recipients of other vaccines, Oxford/AstraZeneca-recipients more body ache, fever, chills (OR: 2.5, 3.0), Moderna-recipients more body ache, fever, chills, rashes (OR: 2.6, 4.3). Hospitalization frequencies were similar across vaccine types. AE frequencies were similar across treatment groups, although chills were less frequent in antimalarial users vs non-users (0.5; 0.3, 0.9). CONCLUSION: While COVID-19 vaccination-related AEs were reported by four-fifths of SLE patients, those were mostly minor and comparable to AEs reported by healthy individuals, providing reassurance regarding COVID-19 vaccination safety in SLE.
APA:
Naveen, R., Nikiphorou, E., Joshi, M., Sen, P., Lindblom, J., Agarwal, V.,... Parodis, I. (2023). Safety and tolerance of vaccines against SARS-CoV-2 infection in systemic lupus erythematosus: results from the COVAD study. Rheumatology, 62(7), 2453-2463. https://doi.org/10.1093/rheumatology/keac661
MLA:
Naveen, R., et al. "Safety and tolerance of vaccines against SARS-CoV-2 infection in systemic lupus erythematosus: results from the COVAD study." Rheumatology 62.7 (2023): 2453-2463.
BibTeX: Download